Author

T. M. Kadia

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 3 Organism:human· 3 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Assay:clinical cohort / trial· 1 Approach:statistical model· 1

Frequent Co-Authors

K. Sasaki· 3 shared C. Bueso-Ramos· 2 shared E. Jabbour· 2 shared F. Ravandi· 2 shared G. Garcia-Manero· 2 shared G. M. Borthakur· 2 shared G. Montalban-Bravo· 2 shared H. Kantarjian· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

K. Sasaki

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor

W. C. Fiskus, J. Piel, M. Collins, M. Hentemann, B. Cuglievan, C. P. Mill, C. E. Birdwell, K. Das, J. A. Davis, H. Hou, A. C. Jain, A. Malovannaya, T. M. Kadia, N. Daver, K. Sasaki, , K. N. Bhalla

This study shows that FHD-286, a BRG1/BRM inhibitor, reduces AML burden and improves survival when combined with Menin or BET inhibitors in xenograft models of AML with MLL1r or mtNPM1.

bioRxiv · Sep 28, 2023Cancer Biology

Clinicopathologic Correlates and Natural History of Atypical Chronic Myeloid Leukemia

G. Montalban-Bravo, R. Kanagal-Shamanna, K. Sasaki, L. Masarova, K. Naqvi, E. Jabbour, C. DiNardo, K. Takahashi, M. Konopleva, N. Pemmaraju, T. M. Kadia, F. Ravandi, N. G. Daver, G. M. Borthakur, Z. E. Estrov, , G. Garcia-Manero

This study examines clinicopathologic features and treatment outcomes in 65 patients with atypical chronic myeloid leukemia, identifying key mutations and predictors of survival.

bioRxiv · Sep 10, 2020Cancer Biology

Only SF3B1 Mutation involving K700E (And Not Other Codons), Independently Predicts Overall Survival in Myelodysplastic Syndromes

R. Kanagal-Shamanna, G. Montalban-Bravo, K. Sasaki, E. Jabbour, C. Bueso-Ramos, Y. Wei, K. S. Chein, T. M. Kadia, F. Ravandi, G. M. Borthakur, K. A. Soltysiak, N. G. Daver, F. Darbaniyan, M. Routbort, K. Patel, , G. Garcia-Manero

This study shows that SF3B1 mutations specifically at codon K700E, but not other codons, are independently linked to better overall survival in myelodysplastic syndromes.

bioRxiv · Sep 4, 2020Cancer Biology